Global Information
회사소개 | 문의 | 비교리스트

자궁내막증 : 세계 의약품 예측과 시장 분석(-2030년)

Endometriosis - Global Drug Forecast and Market Analysis to 2030

리서치사 GlobalData
발행일 2021년 12월 상품코드 1054017
페이지 정보 영문 124 Pages 배송안내
가격
US $ 10,995 ₩ 13,982,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 21,990 ₩ 27,964,000 PDF (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 32,985 ₩ 41,947,000 PDF (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


자궁내막증 : 세계 의약품 예측과 시장 분석(-2030년) Endometriosis - Global Drug Forecast and Market Analysis to 2030
발행일 : 2021년 12월 페이지 정보 : 영문 124 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 자궁내막증 시장 규모는 2020년에 10억 6,100만 달러를 기록하고, 10.6%의 CAGR로 성장하여 2030년에는 29억 달러가 될 것으로 예측됩니다. 시장을 견인하는 주요 요인으로 GnRH 길항제인 레루골릭스(Relugolix)와 린자골릭스(Linzagolix)가 7MM에서 발매된 점 등이 있습니다. 또한 배란을 방해하지 않고 통증을 치료할 수 있는 최초의 자궁내막증 치료제인 퀴나골리드(Quinagolide) 발매나 자궁내막증에 대한 인지도 향상에 의한 진단율 상승 등도 시장 성장을 촉진하고 있습니다. 자궁내막증 파이프라인의 신규성과 기존 자궁내막증 특이적 치료제의 사용 감소를 고려하면, 2030년까지 GnRH 길항제 클래스가 세계 매출의 대부분을 차지할 것으로 예상됩니다.

세계의 자궁내막증(Endometriosis) 시장을 조사했으며, 시장 개요, 질병 개요, 경쟁 상황 평가, 미충족 수요와 기회 평가, 연구개발 전략, 파이프라인 평가, 주요 기업 개요 등 체계적인 정보를 제공합니다.

목차

목차

제1장 자궁내막증 : 주요 요약

  • 자궁내막증 시장은 2020-2030년간 상당한 성장을 나타낸다
  • 현재 치료법은 자궁내막증 시장에 중요한 미충족 수요를 남긴다
  • 자궁내막증 조기 진단에 대한 미충족 수요가 높다
  • 파이프라인 요법은 치료 격차를 해소할 가능성을 나타낸다
  • 의사의 생각

제2장 서론

  • 촉매
  • 관련 보고서
  • 향후 보고서

제3장 질병 개요

  • 병인과 병태생리학
    • 병인
    • 병태생리학
  • 분류 또는 병기결정 체계

제4장 역학

  • 질병 배경
  • 위험인자와 병존질환
  • 세계적 및 역사적 동향
  • 예측 조사 방법
    • 사용된 자료
    • 예측 가정과 방법
    • 자궁내막증 진단된 유병률
    • 복강경 검사 확인 상태별 자궁내막증 진단된 유병률
    • ASRM 스테이지별 자궁내막증 진단된 유병률
    • 표현형별 자궁내막증 진단된 유병률
    • 독일과 영국
    • 복강경 검사를 받고 있는 자궁내막증의 진단된 유병률
    • 병존질환을 수반하는 자궁내막증의 진단된 유병률
  • 자궁내막증 역학 예측(2020-2030년)
    • 자궁내막증 진단된 유병률
    • 자궁내막증 연령별 진단된 유병률
    • 복강경 검사별 자궁내막증 진단된 유병률
    • 스테이지별 자궁내막증 진단된 유병률
    • 표현형별 자궁내막증 진단된 유병률
    • 복강경 검사를 받고 있는 자궁내막증의 진단된 유병률
    • 병존질환을 수반하는 자궁내막증의 진단된 유병률
  • 토론
    • 역학 예측 인사이트
    • COVID-19의 영향
    • 분석의 한계
    • 분석의 강점

제5장 질병 관리

  • 진단과 치료 개요
  • 질병 관리에 관한 KOL의 인사이트

제6장 경쟁 상황 평가

  • 개요

제7장 미충족 수요와 기회 평가

  • 개요
  • 비침습적 진단
  • 질병 인식과 의료 전문가 교육
  • 장기적인 안전성과 내성을 갖춘 더 효과적인 의약품
  • 비호르몬요법
  • 질병 병인과 병태생리학의 더 나은 이해

제8장 연구개발 전략

  • 개요
    • 재처방과 라벨 확장
    • GnRH 길항제 개발을 위한 경쟁
    • 신규 비호르몬요법 개발
  • 임상시험 설계
    • 통증 척도
    • 유효성 툴로서의 삶의 질 평가

제9장 파이프라인 평가

  • 개요
  • 임상 개발의 유망한 의약품

제10장 파이프라인 평가 분석

  • 개요
  • 경쟁 상황 평가

제11장 현재 및 향후 기업

  • 개요
    • AbbVie
    • Bayer
    • Evotec
    • Kissei
    • Pfizer
    • 기타 기업
  • 거래 동향

제12장 시장 전망

제13장 부록

KSM 22.03.10

List of Tables

List of Tables

  • Table 1: Endometriosis: Key Metrics in the 7MM
  • Table 2: Summary of Newly Added Data Types
  • Table 3: Summary of Updated Data Types
  • Table 4: Role of the Different Theories in the Pathogenesis of Endometriosis
  • Table 5: Classifications of Endometriosis
  • Table 6: Risk Factors and Comorbidities for Endometriosis
  • Table 7: The Most Commonly Used Guidelines by Country
  • Table 8: AbbVie Portfolio Assessment, 2021
  • Table 9: Bayer Portfolio Assessment, 2021
  • Table 10: Evotec Portfolio Assessment, 2021
  • Table 11: Kissei Portfolio Assessment, 2021
  • Table 12: Pfizer Portfolio Assessment, 2021
  • Table 13: Additional Companies Assessment, 2021
  • Table 14: Endometriosis Market - Global Drivers and Barriers, 2020-2030
  • Table 15: Key Events Impacting Sales for Endometriosis in the US, 2020-2030
  • Table 16: Endometriosis Market - Drivers and Barriers in the US, 2020-2030
  • Table 17: Key Events Impacting Sales for Endometriosis in the 5EU, 2020-2030
  • Table 18: Endometriosis Market - Drivers and Barriers in the 5EU, 2020-2030
  • Table 19: Key Events Impacting Sales for Endometriosis in Japan, 2020-2030
  • Table 20: Endometriosis Market - Drivers and Barriers in Japan, 2020-2030
  • Table 21: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country

List of Figures

List of Figures

  • Figure 1: Global Sales Forecast by Country for Endometriosis in 2020 and 2030
  • Figure 2: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of Endometriosis During the Forecast Period
  • Figure 3: Roles of estrogen receptor α and estrogen receptor B in normal endometrium and endometrial lesions
  • Figure 4: Endometrial lesions of varying depth
  • Figure 5: Sources of Estradiol in Endometriosis Tissue and Targets of the Current Medical Therapy
  • Figure 6: 7MM, Diagnosed Prevalence of Endometriosis, Women, %, Ages 12-54 Years, 2020
  • Figure 7: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of Endometriosis
  • Figure 8: 7MM, Sources Used to Forecast the Laparoscopy Confirmation Status for the Diagnosed Prevalent Cases of Endometriosis
  • Figure 9: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Endometriosis by ASRM Stage
  • Figure 10: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Endometriosis by Phenotype
  • Figure 11: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Endometriosis Undergoing Laparoscopy
  • Figure 12: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Endometriosis with Comorbidities
  • Figure 13: 7MM, Diagnosed Prevalent Cases of Endometriosis, N, Women, Ages 12-54 Years, 2020
  • Figure 14: 7MM, Diagnosed Prevalent Cases of Endometriosis by Age, N, Women, 2020
  • Figure 15: 7MM, Diagnosed Prevalent Cases of Endometriosis by Laparoscopy Confirmation Status, N, Women, Ages 12-54 Years, 2020
  • Figure 16: 7MM, Diagnosed Prevalent Cases of Endometriosis by Stage, N, Women, Ages 12-54 Years, 2020
  • Figure 17: 7MM, Diagnosed Prevalent Cases of Endometriosis by Phenotype, N, Women, Ages 12-54 Years, 2020
  • Figure 18: 7MM, Diagnosed Prevalent Cases of Endometriosis Undergoing Laparoscopy, N, Women, Ages 12-54 Years, 2020
  • Figure 19: 7MM, Diagnosed Prevalent Cases of Endometriosis with Comorbidity, N, Women, Ages 12-54 Years, 2020
  • Figure 20: Sample Endometriosis Treatment Algorithm
  • Figure 21: Unmet Needs and Opportunities in Endometriosis
  • Figure 22: Overview of the Development Pipeline in Endometriosis
  • Figure 23: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects be Licensed for Endometriosis in the 7MM During the Forecast Period
  • Figure 24: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of Endometriosis During the Forecast Period
  • Figure 25: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the Standards of Care (SOC), GnRH Agonists, Progestins, and Oral Contraceptives
  • Figure 26: Analysis of the Company Portfolio Gap in Endometriosis During the Forecast Period
  • Figure 27: Deal-Making Trends, 2016-2021
  • Figure 28: Global (7MM) Sales Forecast by Country for Endometriosis in 2020 and 2030
  • Figure 29: Sales Forecast by Class for Endometriosis in the US in 2020 and 2030
  • Figure 30: Sales Forecast by Class for Endometriosis in the 5EU in 2020 and 2030
  • Figure 31: Sales Forecast by Class for Endometriosis in Japan in 2020 and 2030

Endometriosis is a disease characterized by the presence of endometrial-like tissue outside of the uterus. This results in chronic pelvic pain and can have significant effects on sufferers' quality of life. Women afflicted with endometriosis are often treated with oral contraceptives and non-steroidal anti-inflammatory (NSAIDs) drugs as a first-line treatment, although these are used off-label and merely treat the pain felt, rather than the cause of the pain. Second-line therapeutics include gonadotropin-releasing hormone (GnRH) agonists and progestins, and in the US, GnRH antagonists. However, endometriosis is difficult to treat and, in some cases, requires surgery in order to remove lesions found in the uterus-and more rarely, distal regions such as the kidney, liver, and even brain.

The launch of GnRH antagonists relugolix and linzagolix across the 7MM will be the main drivers of growth during the forecast period. Other major drivers of growth include the launch of Quinagolide, the first endometriosis therapeutic that can treat pain without interfering with ovulation, and increased awareness of endometriosis, which leads to increased diagnosis rates. The relugolix and linzagolix launch will provide the 5EU and Japanese markets with access to GnRH antagonists for the first time and should also bolster sales of AbbVie's GnRH antagonist Orilissa (elagolix), which is available in the US. Given the novelty of the endometriosis pipeline paired with the decrease in use of existing endometriosis-specific therapeutics, GlobalData expects the GnRH antagonist class to account for the majority of global sales by 2030.

GlobalData projects the therapeutic market for endometriosis within the 7MM will grow from $1.061B in 2020 at a compound annual growth rate (CAGR) of 10.6% to $2.9B by 2030. In particular, GlobalData expects the US market will contribute the most to the endometriosis market sales, accounting for roughly 68% of global sales in both 2020 ($730.65M) and 2030 ($577.1M).

The consensus among interviewed physicians regarding the current treatment landscape of endometriosis is that there are several unmet needs that have persisted for decades, and that current marketed therapies are insufficient in treating pain without significant side effects. Key Opinion Leaders (KOLs) interviewed by GlobalData highlighted the importance of decreasing diagnosis delays, which can be improved by better diagnostic procedures. KOLs also discussed the need for a therapeutic that can treat endometriosis-associated pain while not affecting the patient's ability to conceive and treatments that can be used long-term.

Key Highlights

  • The endometriosis market is currently highly genericized and contains many off-label medications, such as oral contraceptives and NSAIDs, which provide affordable options with limited side effects. These factors create a stiff barrier for entry of novel therapeutics, but pipeline therapeutics will find success due to strong efficacy and safety profiles compared with existing endometriosis marketed therapies.
  • The awareness surrounding endometriosis has improved over the past few years, but remains an area of concern, according to KOLs. Clinicians, physicians, and the general public all need to be more aware of the signs and symptoms of endometriosis in order to decrease diagnosis delays.
  • Women suffering from endometriosis wait an average of 7 years between symptom onset and diagnosis, during which time the disease can progress significantly, potentially affecting fertility. This diagnosis delay can be improved not only with increased awareness of endometriosis, but also better diagnostic techniques, such as biomarkers. Endometriosis can only be officially diagnosed via laparoscopy, which is an invasive and costly surgical procedure.
  • Orilissa was the first novel therapy launched in the endometriosis market in over 10 years when it was marketed in 2018. Thus, there is a need for novel therapies in this space, which should be met by the promising pipeline.

KEY QUESTIONS ANSWERED

  • Treatment for endometriosis should improve over the forecast period, but unmet needs remain.
  • Which unmet needs are the most pressing in the 7MM?
  • Where should pharmaceutical companies focus drug development efforts in order to become a significant player in the space?
  • Novel GnRH antagonists are being developed, with GnRH antagonists reaching the 5EU and Japan for the first time during the forecast period.
  • What are the most promising late-stage candidates and how much they expected to generate over the forecast period?
  • What do KOLs say about their clinical and commercial positioning?
  • An increasing number of companies are investing in women's health and endometriosis with some entering into large-scale collaborations, such as Evotec and Bayer, in an effort to produce more endometriosis therapies.
  • Which have been historically the companies leading the way?
  • What new companies are emerging in the space?

Scope

  • Overview of endometriosis including epidemiology, disease etiology and management.
  • Topline endometriosis drugs market revenue (including off-label adjunct therapeutics used for metabolic benefits), annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.
  • Key topics covered include assessment of current and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU, and Japan over the 10-year forecast period.
  • Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global endometriosis therapeutics market. Insightful review of the key industry drivers, restraints and challenges.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global endometriosis therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global endometriosis market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global endometriosis therapeutics market from 2020-2030.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

1 Endometriosis: Executive Summary

  • 1.1 The Endometriosis Market Will Exhibit Considerable Growth Between 2020 and 2030
  • 1.2 Current Therapies Leave Significant Unmet Needs in the Endometriosis Market
  • 1.3 There Is a High Unmet Need for Earlier Endometriosis Diagnosis
  • 1.4 Pipeline Therapies Present Promise in Closing Treatment Gaps
  • 1.5 What Do Physicians Think?

2 Introduction

  • 2.1 Catalyst
  • 2.2 Related Reports
  • 2.3 Upcoming Reports

3 Disease Overview

  • 3.1 Etiology and Pathophysiology
    • 3.1.1 Etiology
    • 3.1.2 Pathophysiology
  • 3.2 Classification or Staging Systems

4 Epidemiology

  • 4.1 Disease Background
  • 4.2 Risk Factors and Comorbidities
  • 4.3 Global and Historical Trends
  • 4.4 Forecast Methodology
    • 4.4.1 Sources Used
    • 4.4.2 Forecast Assumptions and Methods
    • 4.4.3 Diagnosed Prevalent Cases of Endometriosis
    • 4.4.4 Diagnosed Prevalent Cases of Endometriosis by Laparoscopy Confirmation Status
    • 4.4.5 Diagnosed Prevalent Cases of Endometriosis by ASRM Stage
    • 4.4.6 Diagnosed Prevalent Cases of Endometriosis by Phenotype
    • 4.4.7 Germany and the UK
    • 4.4.8 Diagnosed Prevalent Cases of Endometriosis Undergoing Laparoscopy
    • 4.4.9 Diagnosed Prevalent Cases of Endometriosis with Comorbidities
  • 4.5 Epidemiological Forecast for Endometriosis (2020-2030)
    • 4.5.1 Diagnosed Prevalent Cases of Endometriosis
    • 4.5.2 Age-Specific Diagnosed Prevalent Cases of Endometriosis
    • 4.5.3 Diagnosed Prevalent Cases of Endometriosis by Laparoscopy
    • 4.5.4 Diagnosed Prevalent Cases of Endometriosis by Stage
    • 4.5.5 Diagnosed Prevalent Cases of Endometriosis by Phenotype
    • 4.5.6 Diagnosed Prevalent Cases of Endometriosis Undergoing Laparoscopy
    • 4.5.7 Diagnosed Prevalent Cases of Endometriosis with Comorbidities
  • 4.6 Discussion
    • 4.6.1 Epidemiological Forecast Insight
    • 4.6.2 COVID-19 Impact
    • 4.6.3 Limitations of Analysis
    • 4.6.4 Strengths of Analysis

5 Disease Management

  • 5.1 Diagnosis and Treatment Overview
  • 5.2 Key Opinion Leader Insights on Disease Management

6 Competitive Assessment

  • 6.1 Overview

7 Unmet Needs and Opportunity Assessment

  • 7.1 Overview
  • 7.2 Noninvasive Diagnostics
  • 7.3 Disease Awareness and Education of Medical Professionals
  • 7.4 More Effective Drugs with Long-Term Safety and Tolerability
  • 7.5 Non-Hormonal Therapies
  • 7.6 Better Understanding of the Disease Etiology and Pathophysiology

8 R&D Strategies

  • 8.1 Overview
    • 8.1.1 Reformulations and Label Expansion
    • 8.1.2 The Race for the Development of GnRH Antagonists
    • 8.1.3 Development of Novel Non-Hormonal Therapies
  • 8.2 Clinical Trial Design
    • 8.2.1 Pain Scales
    • 8.2.2 Quality of Life Assessment as an Efficacy Tool

9 Pipeline Assessment

  • 9.1 Overview
  • 9.2 Promising Drugs in Clinical Development

10 Pipeline Valuation Analysis

  • 10.1 Overview
  • 10.2 Competitive Assessment

11 Current and Future Players

  • 11.1 Overview
    • 11.1.1 AbbVie
    • 11.1.2 Bayer
    • 11.1.3 Evotec
    • 11.1.4 Kissei
    • 11.1.5 Pfizer
    • 11.1.6 Additional Companies
  • 11.2 Deal-Making Trends

12 Market Outlook

13 Appendix

Back to Top
전화 문의
F A Q